These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33841165)

  • 1. Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.
    Rodon J; Muñoz-Basagoiti J; Perez-Zsolt D; Noguera-Julian M; Paredes R; Mateu L; Quiñones C; Perez C; Erkizia I; Blanco I; Valencia A; Guallar V; Carrillo J; Blanco J; Segalés J; Clotet B; Vergara-Alert J; Izquierdo-Useros N
    Front Pharmacol; 2021; 12():646676. PubMed ID: 33841165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
    Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
    mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis.
    Sachse M; Tenorio R; Fernández de Castro I; Muñoz-Basagoiti J; Perez-Zsolt D; Raïch-Regué D; Rodon J; Losada A; Avilés P; Cuevas C; Paredes R; Segalés J; Clotet B; Vergara-Alert J; Izquierdo-Useros N; Risco C
    Antiviral Res; 2022 Apr; 200():105270. PubMed ID: 35231500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
    Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
    J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2.
    Biering SB; Van Dis E; Wehri E; Yamashiro LH; Nguyenla X; Dugast-Darzacq C; Graham TGW; Stroumza JR; Golovkine GR; Roberts AW; Fines DM; Spradlin JN; Ward CC; Bajaj T; Dovala D; Schulze-Gamen U; Bajaj R; Fox DM; Ott M; Murthy N; Nomura DK; Schaletzky J; Stanley SA
    ACS Infect Dis; 2021 Aug; 7(8):2337-2351. PubMed ID: 34129317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Simplified Quantitative Real-Time PCR Assay for Monitoring SARS-CoV-2 Growth in Cell Culture.
    Shema Mugisha C; Vuong HR; Puray-Chavez M; Bailey AL; Fox JM; Chen RE; Wessel AW; Scott JM; Harastani HH; Boon ACM; Shin H; Kutluay SB
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32878932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2.
    Chen CZ; Shinn P; Itkin Z; Eastman RT; Bostwick R; Rasmussen L; Huang R; Shen M; Hu X; Wilson KM; Brooks BM; Guo H; Zhao T; Klump-Thomas C; Simeonov A; Michael SG; Lo DC; Hall MD; Zheng W
    Front Pharmacol; 2020; 11():592737. PubMed ID: 33708112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.
    Santos J; Brierley S; Gandhi MJ; Cohen MA; Moschella PC; Declan ABL
    Viruses; 2020 Jun; 12(7):. PubMed ID: 32629804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir.
    Pohl MO; Busnadiego I; Marrafino F; Wiedmer L; Hunziker A; Fernbach S; Glas I; Moroz-Omori EV; Hale BG; Caflisch A; Stertz S
    J Gen Virol; 2021 Jul; 102(7):. PubMed ID: 34319869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor
    Shionoya K; Yamasaki M; Iwanami S; Ito Y; Fukushi S; Ohashi H; Saso W; Tanaka T; Aoki S; Kuramochi K; Iwami S; Takahashi Y; Suzuki T; Muramatsu M; Takeda M; Wakita T; Watashi K
    Front Microbiol; 2021; 12():651403. PubMed ID: 33995308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2.
    Chen CZ; Shinn P; Itkin Z; Eastman RT; Bostwick R; Rasmussen L; Huang R; Shen M; Hu X; Wilson KM; Brooks B; Guo H; Zhao T; Klump-Thomas C; Simeonov A; Michael SG; Lo DC; Hall MD; Zheng W
    bioRxiv; 2020 Aug; ():. PubMed ID: 32839771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plitidepsin: a Repurposed Drug for the Treatment of COVID-19.
    Martinez MA
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33558296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hunting the main protease of SARS-CoV-2 by plitidepsin: Molecular docking and temperature-dependent molecular dynamics simulations.
    Vishvakarma VK; Singh MB; Jain P; Kumari K; Singh P
    Amino Acids; 2022 Feb; 54(2):205-213. PubMed ID: 34807314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety.
    Breining P; Frølund AL; Højen JF; Gunst JD; Staerke NB; Saedder E; Cases-Thomas M; Little P; Nielsen LP; Søgaard OS; Kjolby M
    Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):204-212. PubMed ID: 33176395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic developments for SARS-CoV-2 infection-Molecular mechanisms of action of antivirals and strategies for mitigating resistance in emerging variants in clinical practice.
    Săndulescu O; Apostolescu CG; Preoțescu LL; Streinu-Cercel A; Săndulescu M
    Front Microbiol; 2023; 14():1132501. PubMed ID: 36937282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL
    de Vries M; Mohamed AS; Prescott RA; Valero-Jimenez AM; Desvignes L; O'Connor R; Steppan C; Devlin JC; Ivanova E; Herrera A; Schinlever A; Loose P; Ruggles K; Koralov SB; Anderson AS; Binder J; Dittmann M
    J Virol; 2021 Mar; 95(7):. PubMed ID: 33622961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
    Uzunova K; Filipova E; Pavlova V; Vekov T
    Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.